The abstract presentation, given by Biosergen's COO Tine Olesen, laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the majority of adverse events being infusion-related in the single ascending dose part of the trial and phlebitis in the multi ascending dose part of the trial, and no severe adverse events were seen in the study. Also, basic pharmacovigilance parameters were established.

Biosergen's COO, Tine Olesen, who presented the data to the conference audience, stated, "The engaging discussions and insights shared during the conference further highlight the need for novel anti-fungal treatments. It was a pleasure to be able to contribute to this scientific conversation with our encouraging data on BSG005."

The title of the abstract is "First in human data on BSG005, a genetically engineered polyene macrolide evaluated in a double-blinded placebo-controlled Phase 1 trial" and is accessible on the conference website (https://www.timm2023.org/resources/uploads/sites/92/2023/10/Abstract-book-Accepted-orals-TIMM-11.pdf) and attached to this release.

Currently, Biosergen and its partner Alkem Laboratories Ltd. are preparing a Phase 2 clinical trial in India. The trial will enrol patients suffering from severe fungal infections such as mucormycosis, aspergillosis, and candidiasis. Based on the safety and efficacy profile demonstrated in the preclinical studies and the phase I trials, as also published in the above-mentioned abstract, BSG005 may provide a suitable treatment option for these patients.